| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
11,873 |
6,064 |
$811K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,266 |
8,070 |
$763K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
6,174 |
4,659 |
$636K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
6,855 |
5,564 |
$505K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
13,785 |
8,549 |
$308K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,884 |
4,197 |
$274K |
| 99215 |
Prolong outpt/office vis |
2,594 |
2,008 |
$250K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
6,405 |
5,361 |
$234K |
| 87631 |
|
1,582 |
1,540 |
$216K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
5,478 |
4,327 |
$211K |
| 96127 |
|
10,400 |
8,612 |
$140K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
7,633 |
6,272 |
$67K |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
2,548 |
2,189 |
$65K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
410 |
396 |
$54K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
1,421 |
882 |
$52K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
748 |
618 |
$37K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,781 |
2,080 |
$17K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
444 |
396 |
$15K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
567 |
507 |
$8K |
| 87634 |
|
112 |
85 |
$6K |
| 81002 |
|
2,769 |
1,872 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
382 |
342 |
$5K |
| 99000 |
|
8,537 |
2,956 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
532 |
370 |
$4K |
| 86308 |
|
358 |
305 |
$2K |
| 99050 |
|
244 |
211 |
$1K |
| 36416 |
|
386 |
325 |
$991.29 |
| 87807 |
|
79 |
78 |
$883.88 |
| 71046 |
Radiologic examination, chest; 2 views |
67 |
26 |
$849.20 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
111 |
31 |
$603.26 |
| 36415 |
Collection of venous blood by venipuncture |
103 |
96 |
$275.66 |
| 90686 |
|
43 |
15 |
$272.25 |
| 81025 |
|
46 |
29 |
$225.18 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
185 |
153 |
$104.11 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
933 |
162 |
$100.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
432 |
288 |
$34.01 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
494 |
325 |
$12.48 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
13 |
12 |
$8.17 |
| 94760 |
|
20 |
16 |
$5.08 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
21 |
20 |
$2.98 |
| 99051 |
|
44 |
42 |
$0.00 |